DR. ARCHANA SINHA

DR. SUNIL KUMAR, DR. ANAND SHARAN, DR. MD. RAGHIB TAUHEED

Abstract

Purpose: To evaluate the efficacy of Intravitreal injections of Bevacizumab in patients with macular edema secondary to BRVO. Methods: All the pts >18yrs of age with macular edema secondary to BRVO who had treated with Intravitreal Bevacizumab (1.25mg/0.05ml) were analyzed retrospectively. Clinical variables including BCVA,CMT, number of injections and complications were analyzed.Results: 23 eyes of 23pts (11M/12F) were included in study.The mean follow-up period was 5.8±1.7months.The mean baseline (logMAR) VA was 0.58±0.17 which was significantly improved to 0.36±0.13 at 1 month & 0.33±0.12 at 3 months.The mean CMT at the onset was 355±28.73µm which reduced to 297±28.17µm after 2wks of injection & 291±27.13µm at 1 month.Pts had given an average of 2 injections.There were no adverse effects observed following injections.Conclusion: Intravitreal Bevacizumab can be an effective treatment for macular edema secondary to BRVO. It showed a significant reduction in CMT & improvement in BCVA.

Full Text